Renal Responses to Long-Term Carotid Baroreflex Activation Therapy in Patients With Drug-Resistant Hypertension

Teba Alnima, Peter W. de Leeuw, Frans E. S. Tan, Abraham A. Kroon*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Carotid baroreflex activation has been demonstrated to provide enduring reductions in arterial blood pressure. The aim of this study was to investigate the effect of long-term therapy on renal function. A total of 322 patients were enrolled in the Rheos Pivotal Trial. Group 1 consisted of 236 patients who started baroreflex activation therapy 1 month after device implantation, whereas in the 86 patients from group 2 the device was activated 6 months later. Serum creatinine and urine albumin/creatinine ratio were collected at screening (before device activation), and at months 6 and 12. Multilevel statistical analyses were adjusted for various covariables. Serum creatinine increased from 78 to 84 mu mol/L, and glomerular filtration rate decreased from 92 to 87 mL/min per 1.73 m(2) in group 1 at month 6 (P
Original languageEnglish
Pages (from-to)1334-U425
JournalHypertension
Volume61
Issue number6
DOIs
Publication statusPublished - Jun 2013

Keywords

  • albumin/creatinine ratio
  • carotid baroreflex activation
  • drug-resistant hypertension
  • glomerular filtration rate
  • renal function

Cite this